Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:42:44 2026-02-18 am EST			5-day change	1st Jan Change
308.55 ^DKK	-0.44%		+0.51%	-5.23%

04:15am	Lurpak-maker Arla sees lower dairy prices and boost from protein products	RE
04:14am	NOVO NORDISK : Barclays remains Neutral	ZD

NOVO NORDISK : Gets a Buy rating from Goldman Sachs

Published on 01/22/2026 at 05:23 am EST

MarketScreener with dpa-AFX Analyser

NOVO NORDISK A/S

-0.41%

In a research note published by James Quigley, Goldman Sachs advises its customers to buy the stock. The target price has been lifted and is now set at DKK 436 compared to DKK 352 before.

Latest news about Novo Nordisk A/S

04:15am	Lurpak-maker Arla sees lower dairy prices and boost from protein products	RE
04:14am	NOVO NORDISK : Barclays remains Neutral	ZD
12:17am	EMEA Morning Briefing : Markets Await Fed Minutes	DJ
06:16pm	Health Care Down as Deal Activity Offsets Mixed Earnings -- Health Care Roundup	DJ
Feb. 17	Novo Holdings dissolves share stake in Recursion Pharmaceuticals	RE
Feb. 17	European Stocks Advance in Tuesday Trading; German Inflation Rises to 2.1%	MT
Feb. 17	Dr Reddy's says Wegovy copycat to be priced competitively, with 50-60% discounts feasible	RE
Feb. 17	Dr. Reddy's Looks to Launch Generic Wegovy at 60% Discount	MT
Feb. 17	Dr. Reddy's Looks to Launch Generic Wegovy at 60% Discount, Reuters Reports	MT
Feb. 17	Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable	MT
Feb. 17	Novo Nordisk Gets European Commission Approval for Higher-Dose Wegovy Injectable	MT
Feb. 17	Novo Nordisk Wins EU Approval for Higher Dose of Weight-loss Drug Wegovy	MT
Feb. 17	Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU	DJ
Feb. 17	Novo Nordisk Receives EU Approval for More Effective Wegovy Dosage	FW
Feb. 17	EU approves higher dose of Novo Nordisk's Wegovy	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).

Employees

69,150

Sector

Pharmaceuticals

Calendar

Mar. 26 - Annual General Meeting

More about the company